Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?
Chiara TaniDina ZucchiChiara CardelliElena ElefanteViola SignoriniDavide SchiliròGiancarlo CascaranoLuca GualtieriAnastasiya ValevichGiulia PuccettiLinda CarliChiara StagnaroMarta MoscaPublished in: RMD open (2024)
Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- electronic health record
- big data
- type diabetes
- metabolic syndrome
- mass spectrometry
- adipose tissue
- insulin resistance
- gas chromatography
- smoking cessation
- tandem mass spectrometry